News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bristol-Myers Squibb Company (BMY) Announces Successful Completion of Cash Tender Offer for Shares of Amylin Pharmaceuticals, Inc. (AMLN)



8/8/2012 10:31:07 AM

NEW YORK & PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today the successful completion of the tender offer by Bristol-Myers Squibb Company (“Bristol-Myers Squibb”) through its wholly owned subsidiary, B&R Acquisition Company, for all of the outstanding shares of common stock of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) (“Amylin”) at a purchase price of $31.00 per share. As of the expiration of the offer, 140,550,153 shares of common stock of Amylin were validly tendered and not withdrawn in the tender offer. All of such shares have been accepted for payment in accordance with the terms of the tender offer. The tender offer expired at 5:00 p.m., New York City time, on August 7, 2012. As a result of the tender offer, Bristol-Myers Squibb now owns, together with its subsidiaries, approximately 85.55% of the outstanding shares of Amylin.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES